Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02246374 · ClinicalTrials.gov registry record · NA

ExAblate Transcranial MRgFUS of the Subthalamic Nucleus for Treatment of Parkinson's Disease

A NA study of Parkinson's Disease, sponsored by InSightec.

Active
Registry status
NA
Development phase
7
Enrollment target
1
Study location

NCT02246374 is a NA study of Parkinson's Disease that is active but no longer recruiting, run by InSightec. The registered enrollment target is 7 participants, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02246374, a NA study of Parkinson's Disease, is active but no longer recruiting, sponsored by InSightec.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
7 participants
Enrollment target
1
Study location

Study Summary

This is primarily a safety protocol to evaluate the safety of subthalamotomy using Transcranial ExAblate for treatment of Parkinson's Disease (PD) motor features.

Conditions Studied

Parkinson's Disease

Interventions

  • DEVICE ExAblate Transcranial System

Study Locations (1)

Virginia

  • University of Virginia - Charlottesville

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2014-09
Est. Completion 2026-12
Phase NA

Sponsor

InSightec

38 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02246374

The ClinicalTrials.gov registry entry for NCT02246374 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (99% lower). The listed sponsor is InSightec, which has 38 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which ExAblate Transcranial System is the first listed.

NCT02246374 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.

Frequently Asked Questions

What is clinical trial NCT02246374 about?

NCT02246374 is a clinical study titled "ExAblate Transcranial MRgFUS of the Subthalamic Nucleus for Treatment of Parkinson's Disease". This is primarily a safety protocol to evaluate the safety of subthalamotomy using Transcranial ExAblate for treatment of Parkinson's Disease (PD) motor features.

What is the current status of trial NCT02246374?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 7 participants. The study started on 2014-09. Estimated completion is 2026-12.

What conditions does trial NCT02246374 study?

This clinical trial studies the following conditions: Parkinson's Disease.

What interventions are being tested in trial NCT02246374?

The interventions under investigation include: ExAblate Transcranial System (DEVICE).

Who is sponsoring clinical trial NCT02246374?

This trial is sponsored by InSightec, which has 38 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02246374 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Parkinson's Disease

All registered trials for this condition

Virginia

All trials with a study site in Virginia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.